Drug intelligence / Profile preview

REN-850

Development stage: Unknown
Lead developer: Renovis
Modality: Small Molecules
Administration: Oral

Overview

REN-850 is an investigational oral small molecule drug developed for the treatment of multiple sclerosis. It acts by inhibiting leukocyte trafficking and modulates cell migration driven by multiple chemokine receptors. Preclinical studies have shown that oral administration of REN-850 significantly reduces disease severity in animal models of both multiple sclerosis and rheumatoid arthritis, suggesting potential utility in autoimmune diseases. The drug was developed by Renovis and entered Phase I clinical trials to assess safety, tolerability, and pharmacokinetics in healthy volunteers[1][2].

Beyond the preview

Go deeper on REN-850.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REN-850.

Explore the full profile